Finding new ways to treat childhood cancers
Targeting Pediatric Cancer Vulnerabilities
['FUNDING_OTHER'] · DANA-FARBER CANCER INST · NIH-10931723
This study is exploring new ways to treat kids with acute myeloid leukemia (AML) by using cutting-edge techniques to find better and safer medicines, so young patients can have more effective treatments than the usual chemotherapy and radiation.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10931723 on ClinicalTrials.gov |
What this research studies
This research investigates innovative approaches to target the unique vulnerabilities of pediatric cancers, particularly acute myeloid leukemia (AML). The project aims to overcome existing treatment limitations by utilizing advanced techniques like CRISPR to identify and validate new drug targets. By focusing on the molecular characteristics of childhood cancers, the research seeks to develop more effective and less harmful therapies compared to traditional methods such as chemotherapy and radiation. The principal investigator, a pediatric oncologist, is committed to advancing precision medicine for young patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include children diagnosed with acute myeloid leukemia or other pediatric cancers who are currently facing limited treatment options.
Not a fit: Patients with adult cancers or those whose conditions do not involve the specific vulnerabilities being targeted in this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for children with cancer, significantly improving their chances of survival and quality of life.
How similar studies have performed: While there has been significant progress in adult cancer therapies, this approach to pediatric cancers is relatively novel and aims to address specific challenges that have not been extensively explored.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STEGMAIER, KIMBERLY — DANA-FARBER CANCER INST
- Study coordinator: STEGMAIER, KIMBERLY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.